The need for flexibility in dosing of hypnotic agents

Sleep

Volumn 23, Issue SUPPL. 1, 2000, Pages

  Doghramji, Karl ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Benzodiazepine receptor agonists; Flexible dosing; Insomnia; Triazolam; Zaleplon; Zolpidem

Indexed keywords

BENZODIAZEPINE RECEPTOR STIMULATING AGENT; TRIAZOLAM; ZALEPLON; ZOLPIDEM;

COGNITIVE DEFECT; DOSIMETRY; DRUG HALF LIFE; DRUG SAFETY; HUMAN; INSOMNIA; PALLIATIVE THERAPY; PATIENT COUNSELING; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; REVIEW;

CHRONIC DISEASE; CIRCADIAN RHYTHM; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPNOTICS AND SEDATIVES; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 0034144125     PISSN: 01618105     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. National Center on Sleep Disorders Research; National Heart, Lung, and Blood Institute, and National Institutes of Health. Insomnia: assessment and management in primary care. Sleep 1999;22(suppl 2):S402-S408.
2. Costa E Silva JA, Chase M, Sartorius N, Roth T. Special report from a symposium held by the world health organization and the world federation of sleep research societies: an overview of insomnias and related disorders, recognition, epidemiology, and rational management. Sleep 1996;19:412-416.
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
4. Bonnet MH, Arand DL. Hyperarousal and insomnia. Sleep Med Rev 1997;1:97-108.
5. Ancoli-Israel S, Roth T. Characteristics of insomnia in the United States: results of the 1991 national sleep foundation survey. I. Sleep.1999;22(suppl 2):S347-S353.
6. Shochat T, Umphress J, Israel AG, Ancoli-Israel S. Insomnia in primary care patients. Sleep 1999;22(suppl 2):S359-S365.
7. Mitler M. Nonselective and selective benzodiazepine receptor agonists3/4where are we today? Sleep 2000;23(Suppl 1):
8. Walsh JK, Schweitzer PK. Ten-year trends in the pharmacological treatment of insomnia. Sleep 1999;22:371-375.
9. National Center on Sleep Disorders Research, National Heart, Lung, and Blood Institute, National Institutes of Health. Insomnia: assessment and management in primary care. N1H publication 98-4088, September 1998.
10. Greenblatt DJ. Benzodiazepine hypnotics: sorting the pharmacokinetic facts. J Clin Psychiatry 1991;52(suppl 9):4-10.
11. Kupfer DJ, Reynolds CF III. Management of insomnia. N Engl J Med 1997;336:341-346.
12. Beer B, Jeni JR, Wu W-H, et al. A placebo-controlled evaluation of single escalating doses of CL 284,846, a non-benzodiazepine hypnotic. J Clin Pharmacol 1994;34:335-344.
13. Roth T, Roehrs TA. A review of the safety profiles of benzodiazepine hypnotics. J Clin Psychiatry 1991;52(suppl):38-41.
14. Merlotti L, Roehrs T, Zorick F, et al. Rebound insomnia: duration of use and individual differences. J Clin Pharmacol 1991;11:368-373.
15. Elie R, Rüther E, Farr I, et al. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. J Clin Psychiatry 1999;60:536-544.
16. Darwish M, Danjou P, Paty I, Fournie P. Overall peak psychomotor and memory effects of zaleplon in clinical pharmacology studies. Presented at the 21st Congress Colleguim Internationale Neuropsychologicum (CINP), Glasgow, Scotland, July 12-16, 1998.
17. Balter MB, Uhlenhuth EH. New epidemiologic findings about insomnia and its treatment. J Clin Psychiatry 1992;53(suppl 12):34-39.
18. Roehrs T, Pedrosi B, Rosenthal L, Roth T. Hypnotic self administration and dose escalation. Psychopharmacology 1996;127:150-154.
19. National Institutes of Mental Health. Drugs and insomnia. The use of medications to promote sleep. JAMA 1984;251:2410-2414.
20. Mendelson WB. Comparative results of long-term hypnotic studies. Presented at the American Sleep Disorders Association poster session "Awakening to issues about insomnia," Washington DC, May 15, 1999.
21. Paty I, Danjou P, Fruncillo R, Selmani A. Lack of residual effects with zaleplon compared with zolpidem after administration 5 to 2 hours before awakening. Presented at the 21st Congress Colleguim Internationale Neuropsychologicum (CINP), Glasgow, Scotland, July 12-16, 1998.
22. Walsh JK, Scharf MB, Pollak C, et al. Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia. Sleep 1998;21(suppl):247.